M ild hypothermia, also known as targeted temperature management, is a recommended clinical intervention for neuroprotection. Mild hypothermia is generally defined as the controlled reduction of body temperature to 32-34°C for 12-48 hrs, and has been shown to decrease mortality and improve neurologic outcomes after out-of-hospital cardiac arrest (CA) (1) (2) (3) . Hypothermia alters the pharmacokinetics of several medications commonly used in CA patients. Clinical studies have reported toxic morphine concentrations in neonates (4) , reduced systemic clearances of phenytoin (5) and midazolam (6) in adult traumatic brain injury patients, and temperaturedependent reductions in vecuronium (7) and midazolam (8) clearance in healthy volunteers. Little mechanistic data exist, but our lab and others have suggested an acute decrease in hepatic cytochrome P450 (CYP)-mediated drug metabolism as the cause (9, 10) . In preclinical studies, moderate cooling (30°C) substantially decreased the systemic clearance of a probe for CYP2E1 activity immediately after CA by reducing enzyme binding affinity (11) . It is unknown whether this finding extends equally to other CYPs, the milder temperatures now applied clinically, or medications that are also CYP substrates.
CYP3A is the most important drugmetabolizing enzyme family since it metabolizes approximately 50% of medications (12, 13) . Variations in activity are a critical determinant of drug clearance and are involved in numerous clinically relevant drug-drug interactions observed in critically ill patients (14) . Fentanyl and midazolam, as well as other common intensive care unit medications, rely upon CYP3A for drug elimination. Given the complicated medication regimens that Objectives: Therapeutic hypothermia is widely employed for neuroprotection after cardiac arrest. However, concern regarding elevated drug concentrations during hypothermia and increased adverse drug reaction risk complicates concurrent pharmacotherapy. Many commonly used medications in critically ill patients rely on the cytochrome P450 3A isoform for their elimination. Therefore, our study objectives were to determine the effect of mild hypothermia on the in vivo pharmacokinetics of fentanyl and midazolam, two clinically relevant cytochrome P450 3A substrates, after cardiac arrest and to investigate the mechanisms of these alterations.
Design: Prospective, randomized, controlled study. Setting: University research laboratory. Subjects: Thirty-two adult male Sprague-dawley rats.
Interventions: An asphyxial cardiac arrest rat model was used and mild hypothermia (33°C) was induced 1 hr post injury by surface cooling and continued for 10 hrs to mimic the prolonged clinical application of hypothermia accompanied by intensive care interventions. Fentanyl and midazolam were independently administered by intravenous infusion and plasma and brain concentrations were analyzed using ultraperformance liquid chromatography tandem mass spectrometry. Cytochrome P450 3a2 protein expression was measured and a Michaelis-Menten enzyme kinetic analysis was performed at 37°C and 33°C using control rat microsomes.
Measurements and Main Results: Mild hypothermia decreased the systemic clearance of both fentanyl (61.5  11.5 to 48.9  8.95 mL/min/kg; p  .05) and midazolam (89.2  12.5 to 73.6  12.1 mL/min/kg; p  .05) after cardiac arrest. The elevated systemic concentrations did not lead to parallel increased brain exposures of either drug. Mechanistically, no differences in cytochrome P450 3a2 expression was observed, but the in vitro metabolism of both drugs was decreased at 33°C vs. 37°C through reductions in enzyme metabolic capacity rather than substrate affinity.
Conclusions: Mild hypothermia reduces the systemic clearances of fentanyl and midazolam in rats after cardiac arrest through alterations in cytochrome P450 3a2 metabolic capacity rather than enzyme affinity as observed with other cytochrome P450s. Contrasting effects on blood and brain levels further complicates drug dosing. Consideration of the impact of hypothermia on medications whose clearance is dependent on P450 3A metabolism is warranted. (Crit Care Med 2012; 40:1221-1228)
Key Words: cardiac arrest; drug metabolism; fentanyl; hypothermia; midazolam; pharmacokinetics CA patients receive and the increased risk of adverse drug reactions in the intensive care unit (15) , it is imperative to understand the effects of any new therapies on this enzyme system. Furthermore, current studies have focused on circulating drug levels in the blood whereas the effects of hypothermia on brain tissue levels, and subsequent brain pharmacodynamics, have not been explored. Given the fact that many sedatives and analgesics are metabolized by the CYP3A system and have sites of action within the central nervous system, this represents an important knowledge gap for hypothermia optimization.
Based on these previous studies, we sought to investigate the impact of mild hypothermia on the pharmacokinetics of CYP3A-dependent drug metabolism after CA. We independently evaluated the disposition of fentanyl and midazolam in an animal model of CA. The specific study objectives were: 1) to evaluate the effects of mild therapeutic hypothermia on the systemic clearance and brain penetration of fentanyl and midazolam during an extended period of mild hypothermia in a rat model of CA; and 2) to identify the mechanisms underlying alterations in the systemic clearance by evaluating the effects of hypothermia on hepatic Cyp3a protein expression and in vitro enzyme kinetics.
MATERIALS AND METHODS

Materials and Chemicals
Fentanyl and midazolam for animal dosing were purchased from Hospira (Lake Forest, IL) and Bedford Labs (Bedford, OH), respectively. Analytical standards of these medications, their primary metabolites (norfentanyl and 4-hydroxymidazolam), and deuterated internal standards were purchased from Cerilliant (Round Rock, TX). Organic solvents were purchased from ThermoFisher Scientific (Pittsburgh, PA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
CA and Hypothermia Protocol
All studies were approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh. Thirty-two healthy adult male Sprague-Dawley rats (300-350 g) were purchased from Hilltop Laboratories (Scottsdale, PA) and acclimated for 1 wk before study initiation. The animals were allowed free access to food and water and were housed on a 12hr light/dark cycle.
CA was induced as previously described (16, 17) , with modifications for a prolonged time period of temperature management and steady-state pharmacokinetic studies. Rats were anesthetized with 4% isoflurane via nose cone, endotracheally intubated, and mechanically ventilated to maintain a Pco 2 of 35-45 mm Hg. Neuromuscular blockade was achieved with vecuronium 2 mg/kg and isoflurane was reduced to 1%. The left femoral artery, left femoral vein, and left jugular vein were cannulated for mean arterial pressures/blood gas sampling, pharmacokinetic sampling, and drug administration, respectively. A rectal probe was inserted for continuous body temperature measurement and electrocardiogram leads were placed. After preparative surgery, the CA arrest protocol was initiated. Inhaled anesthetics were washed out with 100% oxygen for 3 mins followed by 2 mins of room air to avoid the confounding cerebroprotective effects of inhaled anesthetics, thereby mimicking clinical CA. Vecuronium was administered and mechanical ventilation was disconnected for 8 mins to induce an asphyxial CA. Approximately 5-6 mins of asystole was confirmed by the electrocardiogram trace. Resuscitation was started by the administration of intravenous epinephrine (0.005 mg/kg) and sodium bicarbonate (1 mEq/ kg), reconnection of the ventilator (100% oxygen, 60 breaths per min), and providing chest compressions (200 per min) until restoration of spontaneous circulation (ROSC). Intravenous fluids (normal saline at 3 mL/ kg/hr) and 0.5% isoflurane were reinitiated 30 mins after ROSC.
Experimental manipulation of temperature was initiated 60 mins after ROSC. Animals were randomized to mild hypothermia (33 6 0.5°C) or controlled normothermia (37 6 0.5°C) with target temperatures achieved via surface cooling (adjusted with ice bags, a fan, heating light, and heating pad) over 30 mins followed by a 15min stabilization period. The delay in hypothermia induction and target temperatures were selected to mimic clinical situations. This temperature was maintained through the 10-hr study duration.
Arterial blood gases, glucose, hematocrit, and electrolytes were measured before arrest; 10 mins, 30 mins, and 60 mins after ROSC; at the end of the cooling and stabilization periods; and hourly during the pharmacokinetic study. Acidosis was corrected via infusion of sodium bicarbonate to maintain a pH 5 7.4. Blood pressure and electrocardiogram were also continuously recorded.
Drug Administration and Pharmacokinetic Sampling
Rats were randomized to one of four groups in a 2 3 2 matrix: normothermia or hypothermia and either midazolam or fentanyl. After the 15-min stabilization period, midazolam (1.5 mg/kg/hr) or fentanyl (50 µg/kg/hr) was dosed by continuous intravenous infusion to clinically relevant, steady-state concentrations over 8 or 10 hrs, respectively. Blood samples (0.3 mL) were collected at baseline, 0.25, 0.5, 1, 2, 4, 6, 7, and 8 hrs for midazolam, and at baseline, 1, 2, 3, 4, 6, 8, 9, and 10 hrs for fentanyl, and plasma was immediately frozen at -20°C. Sample volume was replaced with an equal volume of normal saline.
Brain tissue was also collected to measure drug distribution into this compartment during hypothermia. To minimize potential confounding effects of circulatory blood, transcardial perfusion with normal saline was conducted. Rats were killed by isoflurane overdose and blood washout was achieved by clamping the descending aorta, perforating the right atrium, and injecting 25 mL of ice-cold normal saline into the left cardiac ventricle over 1 min. This rapid perfusion was identical in all treatment groups. Once perfused, brains were removed and frozen in liquid nitrogen and stored at -80°C. Liver tissue from each animal was also collected for Cyp3a expression analysis.
Drug Analysis by Ultraperformance Liquid Chromatography-Tandem Triple-Quadrupole Mass Spectrometry
Fentanyl and midazolam total concentrations were measured in plasma and brain tissue by ultraperformance liquid chromatography tandem triple-quadrupole mass spectrometry using modifications of established methods (8, 18, 19) . Fentanyl and midazolam extractions were performed via 3-mL Oasis MCX or 1-mL Oasis HLB cartridges (Waters, Milford, MA), respectively, following the manufacturer's protocol. For fentanyl, plasma samples were acidified by adding 1 mL of 2% o-phosphoric acid-containing internal standard (15 ng/mL fentanyl-d 5 ) to 100 µL of plasma, before column loading. For midazolam, 1 mL of water containing the internal standard, midazolam-d 4 , was added to 40 µL of plasma. Brain tissue was processed using the same protocol following tissue homogenization using a Tissue Tearor (Biospec products, Bartlesville, OK) and centrifugation at 10,000 rpm (7000 g) for 30 mins at 4°C. After the cartridge eluent was collected and evaporated to dryness under nitrogen, samples were reconstituted in 100 µL 90% 0.15% formic acid/10% acetonitrile for fentanyl, and 200 µL 70% water/30% acetonitrile for midazolam. Chromatographic separation was achieved using a BEH-C18 1.7-µm, 2.1 3 100-mm column (Thermo, Pittsburgh, PA). The fentanyl mobile phase consisted of 0.15% formic acid (solution A) and acetonitrile (solution B) to provide a 0.2 mL/min gradient elution as follows: initially 90%A/10%B for 1 min, then linearly increasing to 100%B over 3 mins and holding for 1 min before returning to initial conditions over 0.5 mins and holding for 2 mins to achieve a total run time of 7.5 mins. Midazolam mobile phase consisted of water containing 5% acetonitrile and 0.005% acetic acid (solution A) and acetonitrile containing 0.005% acetic acid (solution B) to provide a 0.4 mL/ min gradient elution as follows: initially 70%A/30%B for 4.5 mins, then linearly increasing to 30%A/70%B over 0.5 mins and holding for 0.5 mins, before finally returning to initial conditions over 0.5 mins and holding for 1 min to achieve a total run time of 7 mins. Mass spectrometric detection of fentanyl (ion transition, 388→188), norfentanyl (233→84), midazolam (ion transition, 326→291), and 4-hyroxymidazolam (342→325,234) was performed using a TSQ Quantum Ultra MS/MS with an electrospray ionization source (Thermo, Waltham, MA) under positive mode with a collision gas pressure of 1.5 mTorr. Fentanyl-specific conditions include a spray voltage of 3500V; collision energy of 23V; vaporizer and capillary temperature of 200°C and 350°C, respectively; and sheath and auxiliary gas pressures of 60 psi and 35 psi, respectively. Midazolamspecific conditions include a spray voltage of 4000V; collision energy of 27V; vaporizer and capillary temperature of 200°C and 255°C, respectively; and sheath and auxiliary gas pressures of 60 psi and 55 psi, respectively. The XCalibur 2.0 software was used for data acquisition and analysis. Calibration curves for fentanyl and norfentanyl were linear, from 0.125-200 ng/mL (R 2 5 0.9995) and 1-200 ng/mL (R 2 5 0.9990) with lower limits of quantification of 0.125 ng/mL and 1 ng/mL, respectively. Inter-and intra-assay variation was ,15%. Calibration curves for midazolam and 4-hydroxymidazolam were linear, from 5-1000 ng/mL (R 2 5 0.9996) and 0.5-75 ng/mL (R 2 5 0.9932) with lower limits of quantification of 5 ng/mL.
Pharmacokinetic Analysis
Pharmacokinetic parameters were estimated by noncompartmental methods. The plasma steady-state level was determined by averaging the last three plasma concentrations and by verifying that the coefficient of variance in each animal was ,15%. Systemic clearance was calculated by dividing an animal's dosing rate by the steady-state concentration. Brain tissue concentrations (ng/gm wet weight) were divided by the steady-state concentration to determine the brain-to-plasma ratio in each animal.
Microsomal Preparation and Western Blotting
Liver tissue microsomes were prepared by standard methods (20) . Total protein was determined by bicinchoninic acid colorimetric assay (Thermo Pierce, Rockford, IL). Western blotting for Cyp3a2 protein expression was performed on liver harvested at the end of the study (10-12 hrs post CA). Liver microsomes containing 2 µg of protein were denatured with Laemmli sample buffer and heated for 10 mins at 75°C. Samples were resolved on 4%-15% Mini-Protein TGX polyacrylamide gels (Bio-Rad, Hercules, CA), transferred to Millipore IPFL membranes, and blocked with LI-COR Odyssey blocking reagent. Membranes were then probed with 1:4000 primary mouse monoclonal anti--actin (Sigma-Aldrich, St. Louis, MO) and 1:6000 primary rabbit anti-Cyp3a2 (Millipore, Billerica, MA), followed by LI-COR 1:60,000 secondary goat anti-mouse IRDye 680LT and 1:25,000 secondary goat anti-rabbit IRDye 800CW. All membrane incubations occurred in the dark for 1 hr at room temperature while rocking. -actinnormalized Cyp3a2 protein expression was quantified by densitometry using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE). Assay linearity was confirmed inmembrane with controls for intermembrane comparisons.
Enzyme Kinetic Analysis
Microsomes from untreated rats were incubated under conditions of 200 µg protein, 1 mM reduced nicotinamide adenine dinucleotide phosphate and either fentanyl or midazolam in increasing concentrations from 1-150 µM or 1-80 µM, respectively. Duplicate samples were incubated for 12 mins (fentanyl) or 2 mins (midazolam) at either 37°C or 33°C in a circulating water bath. The reactions were stopped by a ten-fold dilution into ice-cold 2% o-phosphoric acid (fentanyl) or incubation buffer (midazolam) containing the deuterated metabolite internal standard. Samples were analyzed for norfentanyl or 4-hydroxymidazolam as described previously.
The effect of incubation temperature on metabolite formation rates was determined through Michaelis-Menten kinetic analysis using Graphpad Prism 5.04 (Graphpad Software, La Jolla, CA). Maximum velocity (V max ) and the Michaelis-Menten constant (K m ) were estimated by nonlinear regression of the raw data. The following equation was fit to the data: 
Statistical Analysis
For comparison of physiologic variables over time under normothermia and hypothermia conditions, a repeated-measures two-way analysis of variance with Bonferroni correction was used. Initial animal weight, resuscitation time, and total bicarbonate administered were compared between groups using unpaired Student's t tests. To determine the effect of hypothermia on systemic clearances and brain-to-plasma ratios, unpaired Student's t tests were used. A p value , .05 was considered statistically significant. All analyses were conducted using Graphpad Prism 5.04 (Graphpad Software, La Jolla, CA).
RESULTS
Temperature Management and Physiologic variables
Surface cooling was effective in achieving and maintaining hypothermia and normothermia temperatures after CA (Fig. 1) . Groups were well matched on weight, resuscitation time, and total bicarbonate replacement ( Table 1 ). The mean Pao 2 over the 8-to 10-hr study period was higher in the hypothermia group after the CA (p , .05), as expected (11, 17) . Hourly mean arterial pressure, pH, Paco 2 , oxygen saturation, blood bicarbonate, lactate, glucose, hematocrit, lactate, and base deficit were not different between groups.
Effect of Hypothermia on the Pharmacokinetics of Fentanyl and Midazolam Following CA
Concentration-time profiles (Fig. 2) and specifically, the last three plasma concentrations, demonstrate that steadystate was achieved. Hypothermia increased plasma concentrations of both fentanyl (n 5 10 hypothermia; n 5 9 normothermia) and midazolam (n 5 7 hypothermia; n 5 6 normothermia). This resulted in a significant decrease in the systemic clearances of fentanyl (20.5% decrease; 61.5 6 11.5 to 48.9 6 8.95 mL/min/kg; p , .05) and midazolam (17.5% decrease; 89.2 6 12.5 to 73.6 6 12.1 mL/min/kg; p , .05) after CA.
In contrast to the increased plasma concentrations, a nonsignificant trend toward decreased brain penetration of fentanyl during hypothermia was observed, as evidenced by a lower brain-to-plasma concentration ratio ( Fig. 3; 1 
Effect of Hypothermia on Cyp3a2 Protein Expression Following CA
Rats killed at the end of the 8-to 10-hr study showed no differences in liver microsomal -actin-normalized Cyp3a2 protein expression ( Fig. 4 ; normothermia, n 5 15, 1.00 6 0.293 vs. hypothermia, n 5 17, 1.10 6 0.320; p 5 .346). Subgroup analyses of rats receiving either midazolam or fentanyl produced similar results. Cyp3a2 and -actin expression was well visualized via infrared imaging and all samples fell within the linear range of detection.
Effect of Temperature on Cyp3a2 Enzyme Kinetics
The best fit nonlinear regression curves and parameters derived from the Michaelis-Menten enzyme kinetic analyses are shown in Figure 5 and Table 2 , respectively. For midazolam, the standard Michaelis-Menten equation fit well with R 2 values of 0.98 for both the 37°C and 33°C curves, and showed no improvement by applying the more complex substrate inhibition Michaelis-Menten model. For fentanyl, however, the norfentanyl formation became nonhyperbolic at higher concentrations. This characteristic "hook" in the upper region of the fentanyl Eadie-Hofstee transformation is representative of substrate inhibition at All values are mean 6 sd of hourly measurements during the 8-to 10-hr pharmacokinetic study. a Statistically significant hypothermia effect (p , .05). high concentrations. Indeed, the substrateinhibition Michaelis-Menten equation fit better (p , .0001), with final R 2 values of 0.98. A comparison of the curves at each temperature showed that hypothermia decreased the Cyp3a2-dependent metabolite formation rates for both drugs (p , .0001). Cooling to 33°C resulted in a significantly lower midazolam enzymatic maximal velocity as parameter estimates for V max decreased (2780 6 60.0 pmol/ mg/min at 37°C to 2430 6 74.8 pmol/ mg/min at 33°C; p 5 .0009). The Eadie-Hofstee plot shows this difference as a changed y-intercept. There was a trend in decreased V max at the lower temperature for fentanyl (2480 6 236 pmol/mg/ min at 37°C vs. 2080 6 203 pmol/mg/ min at 33°C; p 5 .205). No differences in enzyme affinity were observed with either drug during cooling since the Eadie-Hofstee plots had parallel slopes and the Michaelis-Menten constant, K m , was unchanged per model parameter estimates (p 5 .900 for fentanyl and p 5 .438 for midazolam).
DISCUSSION
We report that mild hypothermia, as applied in a highly clinically relevant experimental CA paradigm with a 10-hr study duration, alters the steady-state pharmacokinetics of two commonly used intensive care unit medications, fentanyl and midazolam. Further, we demonstrate that these alterations are not due to changes in hepatic Cyp3a2 protein expression, the primary route of oxidative metabolism of both drugs. Finally, we found that in vitro Cyp3a2-dependent formation rates were decreased by cooling, and that this reduction was the result of changes in maximal velocity rather than enzyme affinity. To mimic the clinical application of hypothermia, we incorporated specific design elements into our CA and hypothermia protocols. In previous work, short duration (3 hrs), low temperature (30°C) hypothermia, and intravenous bolus of probes of CYP pathways were used in proof-of-concept studies to show that cooling could alter drug metabolism post CA (11, 17) . In this study, we delayed the initiation of hypothermia for 1 hr post ROSC, targeted a temperature of 33°C to match the now standard goal range of 32-34°C, and extended the duration of hypothermia to 8-10 hrs. Similarly, we selected the commonly used drugs, fentanyl and midazolam, at a dosing regimen that produced blood concentrations similar to those achieved in patients. The pharmacokinetic design employed continuous infusions to steady-state, to best estimate systemic clearance and to allow for brain-to-plasma tissue distribution ratios. Overall, this work suggests that Cyp3a-dependent metabolism of clinically relevant medications is decreased by mild hypothermia after CA.
Mild hypothermia applied after CA resulted in a modest decrease in the systemic clearances of both midazolam and fentanyl in rats, and is supported by published data. Fritz et al (21) cooled uninjured pigs to 31.6 6 0.2°C and showed that fentanyl concentrations increased 25%. Similarly, the application of 1 hr of 32°C hypothermia to rats after an experimental traumatic brain injury significantly increased fentanyl concentrations by approximately 20% (22) . In both studies, short-term fentanyl infusions were used and assessments were made while the drug was still accumulating, suggesting that differences in the systemic clearances and steady-state concentrations may be far greater. For midazolam, clinical data exist, but are inconsistent. Fukuoka et al (6) reported a "biphasic" concentration change in eight brain-injured patients receiving 32-34°C hypothermia. Despite stable dosing, serum concentrations continued increasing linearly during the 3-to 4-day hypothermic period All data are represented as mean 6 se. a Statistically significant differences, p , .01. (never reaching a steady-state level), and achieved five-fold higher concentrations than in the seven normothermic comparators. During rewarming, the levels fell drastically once body temperatures surpassed 35°C. In their pharmacokinetic analysis, these investigators reported a remarkable .100-fold difference in systemic clearance during hypothermia. Other data, however, suggest a less substantial effect of hypothermia on midazolam pharmacokinetics. In a randomized crossover study of healthy volunteers, we were able to lower core body temperature to 35.4°C and observed a significantly decreased formation of the major metabolite of midazolam (8) . Population pharmacokinetic modeling predicted that midazolam clearance decreased 11.1% for each degree Celsius reduction in temperature from 36.5°C. The current finding of a 20% decrease in the systemic clearance for both fentanyl and midazolam when prolonged mild hypothermia is applied after CA is a smaller magnitude reduction than previously observed. Findings with the CYP2E1 probe, chlorzoxazone, after the same asphyxial CA in rats and 3 hrs of 30°C hypothermia showed a .50% decrease in systemic clearance (11) . Whether the differences in results are primarily attributable to the depth of cooling, which the CYP isoform is involved, or drug characteristics remains to be elucidated. However, the drug hepatic extraction ratios are likely to be an important factor. Contrary to midazolam in humans and chlorzoxazone humans/ rats, both fentanyl and midazolam are high hepatic extraction drugs in rats, with ratios of hepatic clearance to blood flow of 1 and 0.86 respectively (23, 24) . As predicted by the well-stirred model of hepatic clearance (25) (26) (27) , their hepatic clearance may therefore be more dependent on hepatic blood flow rather than significantly affected by changes in hepatic metabolic capacity in this species. Hepatic blood flow was not measured after CA in this experiment, but has been shown to be decreased in hypothermic pigs (21) , rats (28) , and healthy volunteers (29) . Overall, differences in the sensitivity of hepatic blood flow and enzyme metabolic capacity to hypothermia combined with the relative dependency of a given drug on each of these factors for its hepatic clearance may explain these observations.
Mechanistically, we found no differences in Cyp3a2 protein expression by Western blotting, but discovered that cooling to 33°C decreases Cyp3a2mediated fentanyl and midazolam metabolism in vitro through a reduction in enzyme capacity (V max ). Collectively, this suggests that the decrease in systemic clearance of both drugs was due to a direct temperature-related decrease in enzyme activity in vivo rather than alterations in expression. To put the timing of this protein expression analysis into context, we previously reported that CA decreased Cyp3a RNA expression at 24 hrs, but not at 5 hrs post injury in this model (17) . The application of 3 hrs of moderate hypothermia (30°C) attenuated the downregulation of this pregnane X receptor-regulated gene through a proposed mechanism of blocking the increase in interleukin-6 after CA. The current work shows that 8-10 hrs of mild hypothermia does not alter Cyp3a2 protein expression 10-12 hrs after CA relative to controlled normothermia. This suggests that either 10-12 hrs is too early to observe the timedependent downregulation of Cyp3a2 post CA, or that mild hypothermia does not modulate CA-induced changes in Cyp3a2 protein expression. This work is also significant in that it shows that the mild hypothermic temperatures that are applied clinically noncompetitively lower the capacity of Cyp3a for drug metabolism. Previous in vitro Michaelis-Menten modeling of the effect of more aggressive cooling on Cyp2e1 activity suggested a different mode of inhibition. The reduction in chlorzoxazone metabolism at 30°C was attributed to a lower affinity of the enzyme for the drug rather than an enzyme capacity change as K m increased .2 fold and V max remained unaffected (11) . In general, a temperature dependency of V max is more consistent in the enzyme literature, but differences in K m have been also been observed (30) .
Despite increased systemic exposures of both fentanyl and midazolam during mild hypothermia, the brain penetration was not significantly altered. Fentanyl brain-to-plasma concentration ratios trended toward a decrease by mild cooling. These contrasting effects of hypothermia on blood levels and brain penetration suggest a reduction in drug therapeutic index; concentrations are lower than expected in the central nervous system (the site of action) while systemic concentrations are potentially supratherapeutic. A lack of appreciation of this phenomenon may inadvertently lead to increased dosing to achieve efficacy at the expense of toxicity. Blood-brain barrier permeability is known to be determined by drug size, lipophilicity, and transporter protein interactions (31) . Total drug concentration ratios can further be affected by plasma protein or brain tissue binding. Both drugs are lipophilic, small molecules that achieve high brain-to-plasma ratios (.1) in control rats (32, 33) . Fentanyl's brain distribution is also known to depend on both an uptake transporter, likely an organic anion transport protein, and to a minor extent, the efflux transporter pglycoprotein at the blood-brain barrier (34) . It is unclear if rodent blood-brain barrier integrity to small drug molecules early after CA is temperature sensitive. Some evidence for cooling effects on drug transporters has been published. Flux of the p-glycoprotein substrate, digoxin, is decreased 50% at 32°C (35) , and transporter-mediated uptake of vecuronium shows a clear temperature dependency (36) . Whether these in vitro results translate to alterations in brain concentrations due to changes in transporter activity remains an important area of study.
Limitations to our study should be considered. First, the rat asphyxial CA model used in this study, although well established, produces a brain injury that is comprised of selective vulnerable neuronal death and thus may be mild relative to many clinically relevant CA insults. It may therefore underestimate some of the effect of CA and possible interactions between CA-mediated disturbances in metabolism and hypothermia. This is not a serious concern for the current work since this study was designed to evaluate the acute effect of hypothermia, not discern independent effects of CA. Second, our study was conducted in the rat model, which does not ideally mimic human CYP activity, particularly with respect to differences in the extraction ratio of midazolam. Although species differences may affect the magnitude of the findings due to blood flow vs. enzyme dependency, this study does clearly demonstrate the impact of mild hypothermia on fentanyl and midazolam pharmacokinetics. Finally, we focused on CYP metabolic activity and protein expression analysis to gain mechanistic insight into the alterations in systemic clearance. CA and hypothermia may also damage the liver directly and/ or affect hepatic blood flow. Future work should include direct assessments of liver histology and hepatic blood flow to better clarify the mechanisms of altered drug disposition.
CONCLUSIONS
We report, using sustained application of mild hypothermia in a CA model, that mild hypothermia alters the pharmacokinetics of two commonly used medications, fentanyl and midazolam. The systemic clearance of both drugs was decreased, but the resulting elevated systemic concentrations did not lead to an increased brain exposure. Mechanistically, we also demonstrated that the Cyp3a-dependent formation of the primary metabolites of both drugs was decreased at 33°C through a reduction in enzyme metabolic capacity. Our data indicate that the temperatures currently targeted in therapeutic hypothermia protocols that are in clinical use likely alter the disposition of medications whose clearance is dependent on CYP3A metabolism and/or liver blood flow. The observation that plasma concentrations and brain-to-blood ratio changes do not parallel one another further complicates pharmacotherapy. There is a strong need for well-designed pharmacokinetic studies to understand the magnitude and impact of such changes in CA patients. Given the prominent role CYP3A plays in the elimination of many medications, an appreciation of the impact of hypothermia is necessary for safe and effective drug therapy.
